{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:15:16Z","timestamp":1791904516325,"version":"4.3.4"},"reference-count":134,"publisher":"Informa UK Limited","issue":"24","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.2217\/fon-2022-0440","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T05:45:38Z","timestamp":1657604738000},"page":"2713-2732","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":74,"title":["Oncolytic viruses: challenges and considerations in an evolving clinical landscape"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-7730","authenticated-orcid":false,"given":"Ulrich M","family":"Lauer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine VIII,Virotherapy Center T\u00fcbingen,Medical Oncology & Pneumology,Medical University Hospital T\u00fcbingen,\rOtfried-Mueller-Str. 10,\rT\u00fcbingen,\r72076,\rGermany"},{"name":"German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Partner Site T\u00fcbingen,\rOtfried-Mueller-Str. 10,\rT\u00fcbingen,\r72076,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-8249","authenticated-orcid":false,"given":"Julia","family":"Beil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine VIII,Virotherapy Center T\u00fcbingen,Medical Oncology & Pneumology,Medical University Hospital T\u00fcbingen,\rOtfried-Mueller-Str. 10,\rT\u00fcbingen,\r72076,\rGermany"},{"name":"German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Partner Site T\u00fcbingen,\rOtfried-Mueller-Str. 10,\rT\u00fcbingen,\r72076,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-014-0223-y"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06752-9"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215452"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2016-0129"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy033"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.046672-0"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1404"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0216"},{"issue":"5","key":"e_1_3_3_12_1","first-page":"5534","article-title":"Chemovirotherapy for pancreatic cancer: gemcitabine plus oncolytic measles vaccine virus","volume":"18","author":"May V","year":"2019","unstructured":"May V , BerchtoldS, BergerAet al. Chemovirotherapy for pancreatic cancer: gemcitabine plus oncolytic measles vaccine virus. Oncol. Lett.18(5), 5534\u20135542 (2019).","journal-title":"Oncol. Lett."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1529"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113327"},{"issue":"4","key":"e_1_3_3_15_1","first-page":"571","article-title":"Oncolytic viruses & their specific targeting to tumour cells","volume":"136","author":"Singh PK","year":"2012","unstructured":"Singh PK , DoleyJ, KumarGR, SahooAP, TiwariAK. Oncolytic viruses & their specific targeting to tumour cells. Indian J. Med. Res.136(4), 571\u2013584 (2012).","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00195"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00241-1"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00395"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.790150"},{"key":"e_1_3_3_21_1","unstructured":"ClinicalTrials.gov . U.S. National Library of Medicine (2021). https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/794528"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001486"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030544"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13122502"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218310"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg086"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.22.11185-11195.2001"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8110491"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123552"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S154494"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v6.i1.25"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1787981"},{"key":"e_1_3_3_34_1","first-page":"42","article-title":"Poliovirus: generation and characterization of mutants","volume":"15","author":"Burrill CP","year":"2013","unstructured":"Burrill CP , StringsVR, SchulteMB, AndinoR. Poliovirus: generation and characterization of mutants. Curr. Protoc. Microbiol.15, 42 (2013).","journal-title":"Curr. Protoc. Microbiol."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.5"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2014.02.016"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3600-2"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2015.13"},{"key":"e_1_3_3_39_1","first-page":"1","volume-title":"Reoviruses: Entry, Assembly and Morphogenesis.","author":"Guglielmi KM","year":"2006","unstructured":"Guglielmi KM , JohnsonEM, StehleT, DermodyTS. Attachment and cell entry of mammalian orthoreovirus. In: Reoviruses: Entry, Assembly and Morphogenesis.RoyP (Ed.). Springer, Berlin, Heidelberg, 1\u201338 (2006)."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.10.035"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3306"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0574-7"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.831091"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22627"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0799"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00106"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002086"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700585"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300343"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5312"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612811209023313"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01275-6"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207743"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02856-0"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01075-5"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.70"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010228"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124346"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28350"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/v10030108"},{"key":"e_1_3_3_63_1","unstructured":"National Cancer Institute . Common Cancer Types (2022). www.cancer.gov\/types\/common-cancers"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12975"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S36623"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0033"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S165479"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4576"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102786"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003000"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171093"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061416"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1170"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70107-4"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11090856"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.69"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.08.042"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.212"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1412896"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.05.004"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721830"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001701"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S286917"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6803-0"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2018.12.027"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2019-0012"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32172"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25601"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.10.012"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2000.0200"},{"key":"e_1_3_3_93_1","unstructured":"European Medicines Agency . EudraCT public home page (2022). https:\/\/eudract.ema.europa.eu\/"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa215.989"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005"},{"key":"e_1_3_3_96_1","unstructured":"ClinicalTrials.gov . Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND) (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01438112"},{"issue":"3","key":"e_1_3_3_97_1","first-page":"A1","article-title":"Oncolytic vaccinia (Olvi-Vec) primed immunochemotherapy in platinum-resistant\/refractory ovarian cancer","volume":"30","author":"Holloway R","year":"2020","unstructured":"Holloway R , MendivilA, KendrickJet al. Oncolytic vaccinia (Olvi-Vec) primed immunochemotherapy in platinum-resistant\/refractory ovarian cancer. Int. J. Gynecol. Cancer30(Suppl. 3), A1\u2013A210 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"e_1_3_3_98_1","unstructured":"ClinicalTrials.gov . GL-ONC1 oncolytic immunotherapy in patients with recurrent or refractory ovarian cancer (NCT02759588) (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02759588"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy288.108"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13071271"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5010008"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.21"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.505"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3090"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0439"},{"key":"e_1_3_3_106_1","unstructured":"ClinicalTrials.gov. Phase Ib study to evaluate ATP128 VSV-GP128 and BI 754091 in patients with stage IV colorectal cancer (KISIMA-01) (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04046445"},{"key":"e_1_3_3_107_1","unstructured":"AMAL Therapeutics S.A . VSV-GP128 public information (2022). www.biosafety.be\/sites\/default\/files\/bbe21bvw4_pub_en_0.pdf"},{"key":"e_1_3_3_108_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4939-9794-7_19","volume-title":"Oncolytic Viruses. Methods in Molecular Biology.","author":"Breitbach CJ","year":"2020","unstructured":"Breitbach CJ . Considerations for Clinical Translation of MG1 Maraba Virus. In: Oncolytic Viruses. Methods in Molecular Biology.EngelandC (Ed.). Humana, NY, USA, 285\u2013293 (2020)."},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e14637"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.120"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/v8090250"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.03.002"},{"key":"e_1_3_3_113_1","unstructured":"ClinicalTrials.gov. Recombinant measles virus vaccine therapy and oncolytic virus therapy in treating patients with progressive recurrent or refractory ovarian epithelial cancer or primary peritoneal cancer (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00408590"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.305"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.509"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)34352-0"},{"issue":"4","key":"e_1_3_3_117_1","first-page":"P6-21-03-P26-21","article-title":"Abstract P6-21-03: phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV)","volume":"79","author":"Liu M","year":"2019","unstructured":"Liu M , PengK-W, FederspielMet al. Abstract P6-21-03: phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV). Cancer Res.79(Supplement 4), P6-21-03-P26-21-03 (2019).","journal-title":"Cancer Res."},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716435"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002203"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06550.x"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03246"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw378.06"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw378.09"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0216-8"},{"key":"e_1_3_3_125_1","doi-asserted-by":"crossref","unstructured":"Short S KendallJ ChalmersAet al. Combination of reovirus (Pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): long term follow up results of the ReoGlioPhase Ibtrial. American Association for Cancer Research LA USA (8 April 2022).","DOI":"10.1158\/1538-7445.AM2022-CT569"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3260-6"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2078"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1117"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.03.001"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.03.005"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.07.135"},{"issue":"4","key":"e_1_3_3_132_1","article-title":"Abstract OT-32-02: Irene study: phase II study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer","volume":"81","author":"George M","year":"2021","unstructured":"George M , WilliamsN, LustbergMet al. Abstract OT-32-02: Irene study: phase II study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer. Cancer Res.81(Supplement 4), OT-32-02-OT-32-02 (2021).","journal-title":"Cancer Res."},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS216"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113500"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0244"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07121-8"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:43:43Z","timestamp":1719110623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":134,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.2217\/fon-2022-0440"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0440","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}